๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Feasibility of vascular dementia treatment with cholinesterase inhibitors

โœ Scribed by Yansheng Li; John Stirling Meyer; MD Anwarul Haque; Munir H. Chowdhury; Peter Hinh; Minh Quach

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
42 KB
Volume
17
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

โœฆ Synopsis

the range. Overall, it was found that the prevalence of substance misuse in the elderly in-patient population was lower than in the younger population, and a little lower than expected. There may be several reasons for this. Firstly, this study was not speciยฎcally designed for the elderly population. The response rate was 62%, with 19% excluded due to their medical condition. Secondly, the screening instruments used for detecting alcohol and drug misuse in this studyร the CAGE and the AUDITรhave been validated for use in a younger population and are not necessarily reliable or valid when used in the elderly. Lastly, some investigators have questioned the appropriateness of using the DSM-IV and ICD-10 deยฎnition of substance use disorders for the elderly.

In conclusion, speciยฎc screening instruments for detecting substance misuse in the elderly need to be developed, alongside appropriate training of medical teams so that prevention and treatment strategies can be implemented at an early stage.

๐Ÿ“œ SIMILAR VOLUMES

Cholinesterase inhibitors in the treatme
Cholinesterase inhibitors in the treatment of dementia
โœ Maria Luisa Margallo-Lana; Clive Ballard; Chris Morris; David Kay; Stephen Tyrer ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 36 KB

fact may be ascribed to a primarily biological origin of the disease, not correlated with other possible causative events (e.g. chronic somatic diseases). On the other hand, in patients with reactive depressive symptoms a higher prevalence of somatic dysfunction (e.g. number of diseases, Charlson In

Cholinesterase inhibitors in dementia wi
Cholinesterase inhibitors in dementia with Lewy bodiesโ€”a comparative analysis
โœ Mani Bhasin; Elise Rowan; Keith Edwards; Ian McKeith ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 114 KB ๐Ÿ‘ 2 views

## Abstract ## Objective To compare efficacy of different cholinesterase inhibitors (ChEIs) for treating patients with dementia with Lewy bodies (DLB). ## Design Retrospective comparison of three independent clinical studies of ChEI treatment using donepezil, galantamine or rivastigmine in patie

Cholinesterase inhibitors in advanced De
Cholinesterase inhibitors in advanced Dementia with Lewy bodies: increase or stop?
โœ Sanjeet Pakrasi; Alan Thomas; Urs P. Mosimann; David A. Cousins; Debbie Lett; Da ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 44 KB ๐Ÿ‘ 2 views

## Abstract ## Introduction There is little data on stopping cholinesterase inhibitors in Dementia with Lewy bodies (DLB). Equally, it is not known if increasing the dose of cholinesterase inhibitors may help neuropsychiatric symptoms in advanced DLB. ## Method We conducted an open label trial w

Economic evaluation of cholinesterase in
Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies
โœ Anders Gustavsson; Rohan Van Der Putt; Linus Jรถnsson; Rupert McShane ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 79 KB ๐Ÿ‘ 2 views

## Abstract ## Objective To assess the cost effectiveness of cholinesterase inhibitor (ChEI) treatment in patients with Alzheimer's disease (AD) and Dementia with Lewy bodies (DLB). ## Method We used 4โ€month open label followโ€up data from routine memory clinic patients. There were 852 patients w